Skip to main content
Clinical Trials/IRCT20210825052293N1
IRCT20210825052293N1
Recruiting
Phase 3

Evaluation of the effect of selenium supplemention on cancer-related fatigue in outpatient cancer patients and comparison of it with placebo effect in control group

Esfahan University of Medical Sciences0 sites70 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Cancer-related fatigue.
Sponsor
Esfahan University of Medical Sciences
Enrollment
70
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 30 to 60 years of age
  • To be able to read and write
  • Definitive diagnosis of cancer which requires chemotherapy and has been confirmed with pathology findings and authenticated by an oncology subspecialist
  • Not having another treatment regimen that has healing effect on fatigue
  • To have cancer\-related fatigue and score of 40 and above in fatigue questionnaire
  • To tolerate oral medication
  • To cooperate and agree with the study

Exclusion Criteria

  • Patients with known depression undergoing treatment
  • Having anemia
  • Having a disease that prevents patient from continuing participation in study
  • When more than 20% of the questionnaire has not been completed
  • Pregnancy and lactation
  • Renal failure
  • Taking medications such as baloxavir, marboxil, deferiprone, cabotegravir, bisphosphonate derivatives, bictegravir, dolutegravir, eltrombopag, trientine, raltegravir, penicillamine, elvitegravir
  • Known allergy to selenium
  • Hypothyroidism
  • Skin cancer and individulas at high risk for developing squamous cell carcinoma

Outcomes

Primary Outcomes

Not specified

Similar Trials